Patents by Inventor Cheri Lynn Blum

Cheri Lynn Blum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7109330
    Abstract: Compounds of the following formula are provided: In the Formula (I), R1 is —X—R1?; in which R1? is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl, and X is —NH—. R2 is lower alkyl optionally substituted with one, two or three groups chosen from hydroxy, lower alkoxy, and halogen. And R3 is —NR4R5; in which R4 is hydrogen and R5 is lower alkyl substituted with amino; or (ii) R4 and R5 are both lower alkyl optionally substituted with one, two or three groups chosen from hydroxy and amino. It is to be understood that R1? is not cyclohexylmethyl, phenyl, substituted phenyl, benzyl, phenylethyl, or m-hydroxybenzyl. The compounds inhibit CDK-2 activity and are useful for treating disorders characterized by undesirable cell proliferation.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: September 19, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Robert Lum, Cheri Lynn Blum, Richard Mackman, Michael Wick, Steven Schow, Jeff Zablocki, Prabha Ibrahim
  • Patent number: 6794390
    Abstract: A compound having the formula: wherein: R1 is —X—R1′; in which R1′ is lower alkyl, substituted lower alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl, or heterocyclic, and X is —NH—; R2 is isopropyl; and R3 is —NR4R5; in which R4 is hydrogen and R5 is lower alkyl substituted with amino or R4 and R5 are both lower alkyl substituted with one, two or three groups chosen from hydroxy and amino, or an acid addition salt or cationic salt thereof. The compounds inhibit CDK-2 activity and are useful for treating disorders characterized by undesirable cell proliferation.
    Type: Grant
    Filed: August 14, 2001
    Date of Patent: September 21, 2004
    Assignee: CV Therapeutics, Inc.
    Inventors: Robert T. Lum, Cheri Lynn Blum, Richard Mackman, Michael M. Wick, Steven R. Schow
  • Patent number: 6790958
    Abstract: Compounds of the following formula are provided: wherein: R1 is —X—R1′; in which R1′ is alkyl, cycloalkyl, aryl, aralkyl, hetaryl, or heterocyclyl, all of which are optionally substituted; X is —NH; R2 is optionally substituted lower alkyl; and R3 is —NR4R5; in which R4 and R5 independently are hydrogen or lower alkyl optionally substituted by hydroxy or amino; or acid addition salts or cationic salts thereof. The compounds inhibit CDK-2 activity and are useful for treating disorders characterized by undesirable cell proliferation.
    Type: Grant
    Filed: August 14, 2001
    Date of Patent: September 14, 2004
    Inventors: Robert T. Lum, Cheri Lynn Blum, Richard Mackman, Michael M. Wick, Steven R. Schow, Jeffery A. Zablocki, Prabbha Ibrahim
  • Publication number: 20020035252
    Abstract: A 2,6,9-trisubstituted purine composition that is useful for inhibiting cell proliferative disorders and as an antifungal agent.
    Type: Application
    Filed: August 14, 2001
    Publication date: March 21, 2002
    Inventors: Robert T. Lum, Cheri Lynn Blum, Richard Mackman, Michael M. Wick, Steven R. Schow
  • Publication number: 20020032327
    Abstract: A 2,6,9-trisubstituted purine composition that is useful for inhibiting cell proliferative disorders and as an antifungal agent.
    Type: Application
    Filed: August 14, 2001
    Publication date: March 14, 2002
    Applicant: CV Therapeutics, Inc.
    Inventors: Robert T. Lum, Cheri Lynn Blum, Richard Mackman, Michael M. Wick, Steven R. Schow